NKGen Biotech Korea files corrected 2026 half-year report after treasury share omission

NKGen Biotech Korea filed a corrected semi-annual report for the six months ended June 30, 2026 after omitting a treasury share report attachment, adding details on 5,323 common shares and setting a Sept. 5, 2027 cancellation deadline for treasury shares acquired before a March 6, 2026 law change.